2-(4-乙基苯基)噻唑 | 42156-17-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-乙基苯基)噻唑
• 英文名称: 2-(4-ethylphenyl)thiazole
• 英文别名: 2-(4-ethylphenyl)-1,3-thiazole
• CAS: 42156-17-2
• 化学式: C₁₁H₁₁NS
• 分子量: 189.281
• InChiKey: JQZWLKZFQQTQLZ-UHFFFAOYSA-N

物化性质

• 沸点：
  302.2±35.0 °C(Predicted)
• 密度：
  1.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  氯化铱(III) 水合物 、 2-(4-乙基苯基)噻唑 以 水 为溶剂， 生成 [IrCl(2-(4-ethylphenyl)thiazole(-H)-N,C2)2]2
  参考文献：
  名称：

  Color tunable phosphorescent iridium complexes with substituted 2-phenylthiazoles as the cyclometalated ligands

  摘要：

  Several new iridium complexes with substituted 2-phenylthiazoles as the cyclometalated ligands have been synthesized and characterized to try to investigate the effect of the size of the pi system and substituent groups on physical properties. The complexes have the general structure of (C(Lambda)N)(2)Ir(acac), where the C(Lambda)N are 2-phenylthiazole (ptz), 2-(4-methylphenyl)thiazole (mptz), 2-(4-ethylphenyl)thiazole (eptz). The absorption, emission, cyclic voltammetry and thermostability of the complexes were systematically investigated. The experimental results revealed that the maximum emission wavelength in CH(2)Cl(2) at room temperature are in the range 542-547 nm, which is blue shift than that of the known iridium(III) bis(2-phenylbenzothiazolato-N,C(2')) acetyl acetonate (bt)(2)Ir(acac) due to decreasing the size of the pi system in the benzothiazole portion of 2- phenylbenzothiazole ligand. (C) 2008 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ica.2008.04.047

文献信息

• [EN] SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY<br/>[FR] INDUCTEURS DE PETITES MOLÉCULES DE DÉRIVES RÉACTIFS DE L'OXYGÈNE ET INHIBITEURS DE L'ACTIVITÉ MITOCHONDRIALE
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2017155991A1

  公开（公告）日：2017-09-14

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazolinedione structure which function as reactive oxygen species (ROS) inducers and inhibitors of mitochondrial activity within cancer cells (e.g., pancreatic cancer cells), and their use as therapeutics for the treatment of cancer (e.g., pancreatic cancer) and other diseases.

  这项发明属于药物化学领域。具体来说，该发明涉及一类具有喹唑啉二酮结构的小分子，其作为活性氧（ROS）诱导剂和对癌细胞（例如胰腺癌细胞）内线粒体活性的抑制剂，并将它们用作治疗癌症（例如胰腺癌）和其他疾病的药物。
• HIV protease inhibiting compounds
  申请人：DeGoey A. David

  公开号：US20050148623A1

  公开（公告）日：2005-07-07

  A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

  披露了一种公式的化合物作为HIV蛋白酶抑制剂。还披露了用于抑制HIV感染的方法和组合物。
• [EN] SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF<br/>[FR] TRIAZOLOPYRIDINES SUBSTITUÉES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2014153037A1

  公开（公告）日：2014-09-25

  The invention provides compounds having the general formula: [insert formula (I)] (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  该发明提供了具有一般式：[插入式(I)] (I)及其药学上可接受的盐的化合物，其中变量RA，下标n，环A，X2，L，下标m，X1，R1，R2，R3，R4和RN的含义如本文所述，并包含这种化合物的组合物和使用这种化合物和组合物的方法。
• C-9 ALKENYLIDINE BRIDGED MACROLIDES
  申请人：Phan Ly Tam

  公开号：US20080119418A1

  公开（公告）日：2008-05-22

  The present invention discloses compounds of formulae (I), (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明揭示了以下化合物的公式（I），（II）或其药学上可接受的盐，酯或前药：具有抗菌性质。本发明还涉及包括上述化合物的制药组合物，用于治疗需要抗生素治疗的受体。本发明还涉及通过给予包含本发明化合物的制药组合物来治疗受体的细菌感染的方法。本发明还包括制备本发明化合物的方法。
• PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS
  申请人：Dousson Cyril

  公开号：US20100233123A1

  公开（公告）日：2010-09-16

  Provided herein are phosphothiophene and phosphothiazole compounds, for example, of any of Formulae I, IA, IIA, IIIA, IVA, VA, VIA, VIIA, IB, IIB, IIIB, IVB, VB, VIIB and VIIB disclosed herein, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host infected with HCV.

  本文提供了磷硫杂苯和磷硫杂唑化合物，例如公式I、IA、IIA、IIIA、IVA、VA、VIA、VIIA、IB、IIB、IIIB、IVB、VB、VIIB和VIIB中的任何一种，以及包含这些化合物的制药组合物和其制备方法。同时提供了这些化合物用于治疗HCV感染的方法，该方法适用于HCV感染的宿主。